TCGA-4Z-AA87-01A-11R-A39I-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 47.76609724
- os_event
- false
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.550
- MYC_TARGETS_V1+0.520
- E2F_TARGETS+0.470
- G2M_CHECKPOINT+0.450
- UNFOLDED_PROTEIN_RESPONSE+0.450
- DNA_REPAIR+0.370
- OXIDATIVE_PHOSPHORYLATION+0.260
- MTORC1_SIGNALING+0.240
- SPERMATOGENESIS+0.210
- PEROXISOME+0.180
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.600
- INTERFERON_GAMMA_RESPONSE-0.430
- HEDGEHOG_SIGNALING-0.410
- UV_RESPONSE_DN-0.410
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.400
- TNFA_SIGNALING_VIA_NFKB-0.380
- ANGIOGENESIS-0.360
- APICAL_JUNCTION-0.360
- WNT_BETA_CATENIN_SIGNALING-0.340
- TGF_BETA_SIGNALING-0.330
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 2d8cab40-0dda-4d6d-a9ba-83a82a7e1c15 | — | — | 0.930 |
| 2 | TCGA-66-2754-01A-01R-0980-07 | — | cohortA3 | 0.913 |
| 3 | BS_YBJBSRHV | Embryonal tumors | — | 0.912 |
| 4 | TCGA-E7-A85H-01A-11R-A352-07 | — | — | 0.905 |
| 5 | TCGA-AN-A0AK-01A-21R-A00Z-07 | — | C | 0.903 |
| 6 | 20090275.TNBC | — | E | 0.902 |
| 7 | TCGA-HD-A634-01A-11R-A28V-07 | — | — | 0.897 |
| 8 | AUR-AFR3-TTM1-A-1-1-R-A743-41 | — | C | 0.895 |
| 9 | a8ce7460-8ccd-4638-a854-55c4068af6ec | — | — | 0.895 |
| 10 | fea46737-a2b3-49d4-8358-d0737546b6da | — | — | 0.894 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.550 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.520 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.470 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.450 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.450 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.370 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.260 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.240 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.210 | Inavolisib | — uncovered |
| PEROXISOME | 0.180 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.180 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.170 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.150 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.080 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.080 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.070 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.040 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.040 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.040 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.040 | Remibrutinib | — uncovered |